A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00077857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label Study of the Effect of Different Dosing Regimens of Xeloda® in Combination With Taxotere® on Disease Progression in Patients With Locally Advanced and/or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure of chemotherapy with an anthracycline. Patients were randomized to receive either 1250 mg/m\^2 or 825 mg/m\^2 orally twice a day (po bid) on days 1-14 of each 3 week cycle, in combination with Taxotere® 75 mg/m2 intravenous (iv) on day 1 of each 3 week cycle. The anticipated time on study treatment was until disease progression and the target sample size was 440 individuals.
Study identification
- NCT ID
- NCT00077857
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2003 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- Mar 2010 (Actual)
- Last update posted
- May 10, 2013
2003 – 2010
United States locations
- U.S. sites
- 43
- U.S. states
- 23
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Hoover | Alabama | 35216 | — |
| Not listed | Tucson | Arizona | 85715 | — |
| Not listed | Berkeley | California | 94704 | — |
| Not listed | Poway | California | 92064 | — |
| Not listed | Boca Raton | Florida | 33486 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Inverness | Florida | 34452 | — |
| Not listed | Jacksonville | Florida | 32207 | — |
| Not listed | Miami Shores | Florida | 33179 | — |
| Not listed | Port Saint Lucie | Florida | 34952 | — |
| Not listed | Tamarac | Florida | 33321 | — |
| Not listed | Skokie | Illinois | 60076 | — |
| Not listed | Urbana | Illinois | 61801 | — |
| Not listed | Beech Grove | Indiana | 46107 | — |
| Not listed | Des Moines | Iowa | 50314 | — |
| Not listed | Overland Park | Kansas | 66210 | — |
| Not listed | Houma | Louisiana | 70360 | — |
| Not listed | Baltimore | Maryland | 21202 | — |
| Not listed | Baltimore | Maryland | 21236 | — |
| Not listed | Frederick | Maryland | 21701 | — |
| Not listed | Rockville | Maryland | 20850-3348 | — |
| Not listed | Boston | Massachusetts | 02118 | — |
| Not listed | Detroit | Michigan | 48202-2689 | — |
| Not listed | Kalamazoo | Michigan | 49007 | — |
| Not listed | Jefferson City | Missouri | 65109 | — |
| Not listed | Saint Joseph | Missouri | 64507 | — |
| Not listed | Paramus | New Jersey | 07652 | — |
| Not listed | Summit | New Jersey | 07901 | — |
| Not listed | Williamsville | New York | 14221 | — |
| Not listed | Canton | Ohio | 44718 | — |
| Not listed | Mayfield Heights | Ohio | 44124 | — |
| Not listed | Allentown | Pennsylvania | 18104 | — |
| Not listed | Kingston | Pennsylvania | 18704 | — |
| Not listed | Charleston | South Carolina | 29406 | — |
| Not listed | Columbia | South Carolina | 29203 | — |
| Not listed | Collierville | Tennessee | 38017 | — |
| Not listed | Knoxville | Tennessee | 37920 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Colchester | Vermont | 05446 | — |
| Not listed | Abingdon | Virginia | 24211 | — |
| Not listed | Walla Walla | Washington | 99362 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00077857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2013 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00077857 live on ClinicalTrials.gov.